en · de · es · fr · pt
melanotan-2-notes.peptides4800.com › Info › Background And Chemical Profile — Questions and Answers

Background And Chemical Profile — Questions and Answers

By Editorial Desk · published 2025-08-10 · last reviewed 2025-09-26 · Info

A practical reference on afamelanotide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2025-09-26. Anything still debated is marked as such rather than presented as settled.

Background and Chemical Profile

The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.

Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.

Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.

Background and Mechanism of Melanotan-2

Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.

Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.

Melanotan-2 at a glance

PropertyValueNotes
Molecular classSynthetic cyclic heptapeptideAnalog of alpha-MSH with an internal lactam bridge
Molecular weightApproximately 1024 daltonsFree base value; salt forms differ
AppearanceWhite to off-white powderUsually supplied as a lyophilized solid
SolubilityFreely soluble in waterPoorly soluble in nonpolar solvents
Typical storage−20 °C, dry, protected from lightRepeated freeze-thaw cycles degrade peptides

Chemical Background and Receptor Activity

Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.

Related pages on this site

Identity and Chemical Background

Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.

Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.

Notes from published material

The Global Polio Eradication Initiative (1988) Maternal and Neonatal Tetanus Elimination (1989) The Measles & Rubella Initiative (2001) The End TB strategy (2015) The Global Health Sector Strategy on Viral Hepatitis (2016) The Global Technical Strategy for Malaria (2016) The Eliminate Yellow Fever Epidemics Strategy (2017) The Global Strategy to Accelerate the Elimination of Cervical Cancer (2020) The Global Roadmap to Defeat Meningitis (2020) Polio is very close to being eradicated as of 2026.

== Fireproof vaults == Fireproof vaults protecting paper documents are built of concrete or masonry. The Municipal Code of Chicago, in its flammable-liquids chapter, defines a standard fireproof vault as a room whose walls, floor and ceilings are built of reinforced concrete or masonry of not less than two-hour fire-resistive construction. NFPA 232, a U.S. standard for the protection of records, defines a standard records vault as a completely fire-resistive enclosure used exclusively for records storage, and requires that its walls be noncombustible and of fire-resistive construction throughout. In the event of a fire, steam is released into the chamber of a concrete vault, rapidly raising the temperature to 212 °F (100 °C) and the relative humidity to 100%. Concrete vaults are not listed for the storage of non-paper media, because the steam that concrete releases in a fire drives the interior beyond the temperature and humidity limits that the UL 72 test procedure sets for media. The UL 72 classification of records-protection equipment, as restated in NFPA 232, sets the interior temperature and relative-humidity limits that must not be exceeded during the rated time of a standard fire test, the three classes being:

=== Cytochrome electron carriers === Cytochromes are proteins that contain iron. They are found in two very different environments. Some cytochromes are water-soluble carriers that shuttle electrons to and from large, immobile macromolecular structures imbedded in the membrane. The mobile cytochrome electron carrier in mitochondria is cytochrome c. Bacteria use a number of different mobile cytochrome electron carriers. Other cytochromes are found within macromolecules such as Complex III and Complex IV. They also function as electron carriers, but in a very different, intramolecular, solid-state environment. Electrons may enter an electron transport chain at the level of a mobile cytochrome or quinone carrier. For example, electrons from inorganic electron donors (nitrite, ferrous iron, electron transport chain) enter the electron transport chain at the cytochrome level. When electrons enter at a redox level greater than NADH, the electron transport chain must operate in reverse to produce this necessary, higher-energy molecule. It has been observed that inter-protein electron transport between cytochromes c and c1 (complex III) depends on pH and the presence of oxygen, suggesting that protons and superoxide may act as redox mediators in the long-distance electron transport process through the aqueous solution.

=== CaMK2A === CaMKIIA is one of the major forms of CamKII. It has been found to play a critical role in sustaining activation of CamKII at the postsynaptic density. Studies have found that knockout mice without CaMKIIA demonstrate a low frequency of LTP. Additionally, these mice do not form persistent, stable place cells in the hippocampus.

Sources: en.wikipedia.org

Background from the literature

=== 30 July === Russia claimed to have taken the village of Pivdenne, east of Toretsk. The Ukrainian 79th Tavrian Air Assault Brigade claimed to have repelled a major Russian assault on Kurakhove, inflicting losses of 12 armored vehicles, eight tanks, nine motorcycles, and one buggy destroyed, 36 Russian soldiers killed and 32 others injured. The Ukrainian military claimed to have struck an oil depot in Russia's Kursk Oblast following an air attack.

The informal abbreviations of job titles may be a source of confusion. In the United States, medical laboratory scientist (ASCP) and medical technologists (AMT) or (AAB) are often called "med techs" (based on the era in which they were known as "medical technologists"), but this shorthand term is shared by other healthcare employees, including pharmacy techs, radiographers (also known as radiologic technologists), and respiratory therapists. In the United States there is a formal distinction between an MLT and a MT/MLS. Often, MT/MLS have at least a bachelor's degree, while MLT have an associate degree. However, due to grandfathering rules and certification requirements between the boards of registry, some MT/MLS may only have an associate degree. Scientists and technologists generally earn a higher income than technicians, have more responsibilities, and have more opportunities for advancement. In the United Kingdom, there are defined training pathways leading to professional registration as either a clinical scientist, or as a biomedical scientist. The role descriptions for these healthcare scientists are very different, where clinical scientists generally undertake non-routine research and development, as well as improving and providing clinical service using scientific expertise. Biomedical scientists in the United Kingdom are similar to the role of MLT and MT/CLS described above, and have similar regulatory requirements for professional regulation. Clinical scientists in the United Kingdom may struggle with a lack of professional recognition.

Beta blockers, also spelled β-blockers and also sometimes known as β-adrenergic receptor antagonists, are a class of medications predominantly used to manage abnormal heart rhythms (arrhythmia) and to protect the heart from a second heart attack after the first one (secondary prevention). They are also used widely to treat high blood pressure, though they are no longer the first choice for initial treatment of most people. They can also be used to treat anxiety – a notable example being the situational use of propranolol to help dampen the physical symptoms of performance anxiety. Beta blockers are competitive antagonists that block the receptor sites for the endogenous catecholamines epinephrine (adrenaline) and norepinephrine (noradrenaline) on adrenergic beta receptors, of the sympathetic nervous system, which mediates the fight-or-flight response. β-adrenergic receptors are found on cells of the heart muscles, smooth muscles, airways, arteries, kidneys, and other tissues that are part of the sympathetic nervous system and lead to stress responses, especially when they are stimulated by epinephrine (adrenaline). Beta blockers interfere with the binding to the receptor of epinephrine and other stress hormones and thereby weaken the effects of stress hormones. Some beta blockers block activation of all types of β-adrenergic receptors and others are selective for one of the three known types of beta receptors, designated β1, β2, and β3 receptors. β1-Adrenergic receptors are located mainly in the heart and in the kidneys.

dadantii possesses the ability to spread to new regions of the host and other areas may begin to display symptoms. Colonization within the xylem restricts flow of water causing loss of turgor pressure and wilting of foliage and stems. Restricted movement of important plant compounds eventually lead to death of the host.

After at least three months, other effects are expected, such as the deepening of the voice and changes in sexual organs (such as atrophy of vaginal tissues, and increased clitoral size). Regular monitoring by an endocrinologist is a strong recommendation to ensure the safety of individuals as they transition. Access to hormone replacement therapy has been shown to improve quality of life for people in the female-to-male community when compared to female-to-male people who do not have access to hormone replacement therapy. Feminizing therapy has also been found to improve well-being. Interestingly, one systematic review determined that "Overall, the qualitative literature tended to support positive changes in well-being among people after starting feminizing hormone therapy, although often with the qualification that improvements in well-being were attributed to satisfaction with changes in appearance rather than to direct effects of hormones on psychosocial states." Hormone therapy for transgender individuals has been shown in medical literature to be safe, when supervised by a qualified medical professional. Monitoring of risk factors associated with hormone replacement therapy, such as prolactin levels in transgender women and polycythemia levels in transgender men, are crucial for the preventive health care of transgender people taking these treatments. Many transgender people lack access to a supportive, high quality, non-discriminatory health care system.

Sources: en.wikipedia.org

Frequently asked questions

What is melanotan-2?

It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.

How does it differ from melanotan-1?

Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.

Is it the same as bremelanotide?

No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.

Is melanotan-2 a natural hormone?

No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.

Network